BIO Supports Permanent Reauthorization of Programs to Encourage Development of Lifesaving Medications for Children

H.R. 4274 will encourage continued investment in pediatric research.</p>

Washington, D.C. (March 28, 2012) – BIO President and CEO Jim Greenwood issued the following statement in support of H.R. 4274 which will reauthorize the Best Pharmaceuticals for Children Act (BCPA) and Pediatric Research Equity Act (PREA):

“We thank Representatives Mike Rogers (R-MI), Anna Eshoo (D-CA) and Ed Markey (D-MA) for their leadership in introducing legislation to reauthorize BPCA and PREA in order to continue to incentivize the development of lifesaving therapies for children.

“Together, BPCA and PREA have been remarkably successful in ensuring the medicines used by children are tested and appropriately labeled for their use, contributing to improved health outcomes for pediatric patients.  According to the FDA, these laws have resulted in nearly 425 pediatric labeling changes since 1998.  America’s biopharmaceutical companies are currently researching more than 280 medicines to help meet the unique health care needs of children and adolescents.

“We are particularly pleased that this legislation will make both programs permanent.  This will encourage continued investment in pediatric research and ensure that new drugs and biologics will be used safely and appropriately in pediatric patients.

“We encourage Congress to promptly pass this legislation.”